Skip to main content

Table 1 Baseline characteristics of patients in the training and the validation cohort

From: A novel prognostic model predicting the long-term cancer-specific survival for patients with hypopharyngeal squamous cell carcinoma

  All cohort
(N = 2021)
Training cohort
(N = 1415)
Validation cohort
(N = 606)
P value
Age
Median (IQR) 63 (56–70) 63 (56–70) 63 (56–71) 0.606
Year of Diagnosis
2010 344 (17.0%) 227 (16.0%) 117 (19.3%) 0.450
2011 335 (16.6%) 234 (16.5%) 101 (16.7%)  
2012 356 (17.6%) 261 (18.4%) 95 (15.7%)  
2013 364 (18.0%) 255 (18.0%) 109 (18.0%)  
2014 319 (15.8%) 227 (16.0%) 92 (15.2%)  
2015 303 (15.0%) 211 (14.9%) 92 (15.2%)  
Sex
Male 1681 (83.2%) 1177 (83.2%) 504 (83.2%) 0.995
Female 340 (16.8%) 238 (16.8%) 102 (16.8%)  
Race
White 1521 (75.3%) 1061 (75.0%) 460 (75.9%) 0.906
Black 352 (17.4%) 249 (17.6%) 103 (17.0%)  
Other 148 (7.3%) 105 (7.4%) 43 (7.1%)  
Grade
Grade I-II 853 (42.2%) 601 (42.5%) 252 (41.6%) 0.909
Grade III-IV 687 (34.0%) 477 (33.7%) 210 (34.7%)  
Unknown 481 (23.8%) 337 (23.8%) 144 (23.8%)  
AJCC Stage
I 71 (3.5%) 44 (3.1%) 27 (4.5%) 0.221
II 172 (8.5%) 118 (8.3%) 54 (8.9%)  
III 357 (17.7%) 241 (17.0%) 116 (19.1%)  
IV 1421 (70.3%) 1012 (71.5%) 409 (67.5%)  
T stage
T1 194 (9.6%) 132 (9.3%) 62 (10.2%) 0.722
T2 692 (34.2%) 491 (34.7%) 201 (33.2%)  
T3 509 (25.2%) 349 (24.7%) 160 (26.4%)  
T4 626 (31.0%) 443 (31.3%) 183 (30.2%)  
N stage
N0 480 (23.8%) 328 (23.2%) 152 (25.1%) 0.561
N1 380 (18.8%) 263 (18.6%) 117 (19.3%)  
N2 1036 (51.3%) 731 (51.7%) 305 (50.3%)  
N3 125 (6.2%) 93 (6.6%) 32 (5.3%)  
M stage
M0 1839 (91.0%) 1280 (90.5%) 559 (92.2%) 0.199
M1 182 (9.0%) 135 (9.5%) 47 (7.8%)  
Treatment
Surgery
  Yes 356 (17.6%) 252 (17.8%) 104 (17.2%) 0.726
  No 1665 (82.4%) 1163 (82.2%) 502 (82.8%)  
Radiotherapy
  Yes 1642 (81.2%) 1148 (81.1%) 494 (81.5%) 0.838
  No 379 (18.8%) 267 (18.9%) 112 (18.5%)  
Chemotherapy
  Yes 1434 (71.0%) 1015 (71.7%) 419 (69.1%) 0.240
  No 587 (29.0%) 400 (28.3%) 187 (30.9%)  
  1. IQR: interquartile range
\